CervoMed Inc (CRVO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.56+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRVO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -64.1% |
| Our one-year growth estimate | diamond | -65.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 0.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRVO — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-06-22
Unregistered Sales of Equity Securities. The information set forth in
Why it matters: M&A activity can show how CervoMed might grow and where it is headed.
Supportive ifA press release talks about successful integration or benefits from the M&A deal.
Worry ifNo updates or negative news regarding the M&A agreement.
Why it matters: Updates on cash will show financial health and if trials can be funded.
Watch forCash position is over $24 million, which means the runway is extended.
Also watch forCash position is below $20 million, raising worries about funding for trials.
Why it matters: Earnings reports show how well the company is doing and what to expect.
Watch forEarnings report shows revenue growth or better financial metrics.
Also watch forThe earnings report shows ongoing losses or bad financial trends.
Why it matters: Finding a partner is key to move neflamapimod into Phase 3 trials for DLB.
Supportive ifA partnership with a big drug company will help fund the Phase 3 trial.
Worry ifNo partnership announcement by the end of 2026, delaying the Phase 3 trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$265 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $881 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,859 loss on $10,000 · 78.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Extending the cash runway is crucial for funding ongoing trials and operations.
Supportive ifCervoMed gets more funding or partners. This will help them have cash after Q3 2026.
Worry ifCash may run out before Q3 2026. This will limit what they can do.
Why it matters: Funding is crucial for CervoMed to move forward with the Phase 3 trial. Lack of funding could delay or halt progress.
Worry ifCervoMed gets enough funding for the Phase 3 trial. This comes from partnerships or investments.
Less concerning ifCervoMed announces a funding shortfall or delays in securing funds for the trial.
Why it matters: Starting the Phase 3 trial is a big step for CervoMed. It shows progress in drug development.
Supportive ifAnnouncement of the start of the Phase 3 trial for neflamapimod in DLB.
Worry ifDelay in starting the Phase 3 trial beyond 2026.
Why it matters: This data could show if neflamapimod works. It may help with more development.
Supportive ifInitial biomarker data from the Phase 2a trial in nfvPPA is reported in mid-2026.
Worry ifNo early biomarker data is shared. The data may not be clear.
Why it matters: Data from the nfvPPA trial could show how well neflamapimod works. This may affect future funding and partnerships.
Watch forGood 12-week biomarker data will be shared at the ISFTD conference in October 2026.
Also watch forUnclear or negative data will be shown at the ISFTD conference.
Why it matters: The dosing plan affects how well the treatment works. Good dosing guidelines can improve results.
Watch forCervoMed confirms the 50 mg TID dosing strategy for the Phase 3 trial based on new data.
Also watch forCervoMed changes the dosing plan from 50 mg TID after more analysis.
Why it matters: Funding is important for operations. It affects CervoMed's ability to keep its projects going.
Worry ifThe company announced it has enough money to pay for costs until September 2026.
Less concerning ifNews about funding shortages or delays in getting needed money.
Why it matters: Good data could show neflamapimod works for nfvPPA and help investors feel confident.
Supportive ifData from a 12-week study will be shared at the ISFTD conference in October 2026.
Worry ifData shows no major improvement in biomarkers, raising doubts about how well the treatment works.
Why it matters: Dosing the first patient would be a big step for neflamapimod's clinical uses.
Supportive ifAnnouncement of the first patient dosed in the EXPERTS-ALS trial by the end of 2026.
Worry ifNo news on patient dosing by the end of 2026 may mean delays in the trial.
Why it matters: Topline data could show how well neflamapimod helps people recover from strokes. It may also help future trials.
Watch forTopline data from the RESTORE trial shows good progress in recovery measures.
Also watch forTopline data shows no big improvement. This raises doubts about the drug's help with stroke recovery.